Xenon Pharmaceuticals Inc.

NASDAQ:XENE

Biotechnology

Healthcare
$37.56 -0.55%

-$0.29 today

Market cap
$3.69B
Beta
0.63
P/E (TTM)
-12.1
EPS (TTM)
-$4.39
52W Low $30.00High $63.95

Volume 1.28M

Average 1.16M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$279.12M

FY 2025 · Annual

Investing Cash Flow

$218.00M

FY 2025 · Annual

+32.1% YoY

Financing Cash Flow

$117.11M

FY 2025 · Annual

+865.5% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(78.88M)(125.37M)(182.39M)(234.33M)(345.91M)
Depreciation & Amortization906K1.41M3.54M2.56M2.54M
Deferred Income Tax58K(44K)(292K)(8.86M)(3.2M)
Stock-Based Compensation10.02M20.38M32.37M50.72M53.71M
Change in Working Capital(2.65M)(676K)5.64M5.71M4.36M
Accounts Receivables(459K)1.76M130K(614K)104K
Inventory(2.97M)0000
Accounts Payables2.97M8.06M3.93M8.53M5.51M
Other Working Capital(2.19M)(10.5M)1.57M(2.2M)(1.26M)
Other Non-Cash Items1.05M5.88M(4.19M)2.82M9.38M
Operating Cash Flow(69.5M)(98.43M)(145.33M)(181.39M)(279.12M)
Capital Expenditures(2.05M)(2.89M)(5.62M)(3.08M)(799K)
Acquisitions (Net)(144.75M)296M000
Purchases of Investments(389.47M)(551.14M)(793.91M)(532.27M)(355.66M)
Sales of Investments144.75M258.03M682.35M700.34M574.45M
Other Investing Activities144.75M(296M)000
Investing Cash Flow(246.77M)(296M)(117.17M)165M218M
Debt Repayment00000
Common Stock Issued447.28M277.77M353.49M12.08M117.11M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities260K705K35K47K0
Financing Cash Flow447.54M278.47M353.52M12.13M117.11M
Effect of Forex Changes(592K)(2.48M)376K(1.67M)458K
Net Change in Cash130.68M(118.45M)91.4M(5.93M)56.45M
Free Cash Flow(71.55M)(101.32M)(150.94M)(184.46M)(279.92M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$345.9M
+ D&A$2.5M
+ Stock-Based Comp$53.7M
- Deferred Tax-$3.2M
+ Working Capital$4.4M
+ Other Non-Cash$9.4M
= Operating Cash Flow-$279.1M
- Capex-$799.0K
= Free Cash Flow-$279.9M

Analysis

FY2025 free cash flow is -$279.9M. FCF conversion is 80.9% of net income. Operating cash flow was -$279.1M, with capex of -$799.0K. The largest bridge item is Stock-Based Comp at $53.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 9, 2026
S-8S-8 filingNov 9, 2026
10-QQuarterly reportNov 9, 2026
SC 13G/ASC 13G/A filingNov 6, 2026
SC 13GSC 13G filingNov 6, 2026

Does XENE generate free cash flow?

Xenon Pharmaceuticals Inc. (XENE) generated -$279.92M of free cash flow in fiscal 2025.

How much operating cash flow does XENE produce?

Operating cash flow was -$279.12M, before capital expenditures of $799,000.00.